In this study, we firstly found Hoxaas3 was up-regulated in PF, and promoted fibrogenesis, indicating that Hoxaas3 might be a useful biomarker and a candidate drug target for IPF. The gene discussed is HOXA-AS3; the disease is idiopathic pulmonary fibrosis.